Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (Q38389823)

From Wikidata

Jump to navigation Jump to search

scientific article published on July 2015

Language	Label	Description	Also known as
English	Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease	scientific article published on July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (English)

1 reference

Europe PubMed Central

2 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

André J Scheen

1

1 reference

Europe PubMed Central

2 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2015

1 reference

Europe PubMed Central

2 September 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

2 September 2017

54

1 reference

Europe PubMed Central

2 September 2017

691-708

1 reference

Europe PubMed Central

2 September 2017

7

1 reference

Europe PubMed Central

2 September 2017

https://scigraph.springernature.com/pub.10.1007/s40262-015-0264-4

0 references

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

SGLT inhibitors in management of diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

SGLT2 inhibitors in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Dapagliflozin: a review of its use in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Ipragliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Tofogliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

SGLT2 inhibitors: their potential reduction in blood pressure

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal effects of dapagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Luseogliflozin: First Global Approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-015-0264-4

1 reference

Europe PubMed Central

2 September 2017

Dimensions Publication ID

0 references

release_ipbtx2kv3rbo7pbo4njmg24gzq

1 reference

https://api.fatcat.wiki/v0/release/ipbtx2kv3rbo7pbo4njmg24gzq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38389823&oldid=2143924463"